• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Phibro Animal Health Corporation

    4/28/25 2:22:21 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PAHC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    PHIBRO ANIMAL HEALTH CORP

    (Name of Issuer)


    Class A

    (Title of Class of Securities)


    71742Q106

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    71742Q106


    1Names of Reporting Persons

    PZENA INVESTMENT MANAGEMENT LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    616,071.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    723,830.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    723,830.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.6 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    PHIBRO ANIMAL HEALTH CORP
    (b)Address of issuer's principal executive offices:

    GLENPOINTE CENTRE EAST, 3RD FLOOR, GLENPOINTE CENTRE EAST, 3RD FLOOR, TEANECK, NEW JERSEY, 07666.
    Item 2. 
    (a)Name of person filing:

    Pzena Investment Management, LLC
    (b)Address or principal business office or, if none, residence:

    320 Park Avenue, 8th floor New York, NY 10022
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Class A
    (e)CUSIP No.:

    71742Q106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    723,830
    (b)Percent of class:

    3.6  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    616,071

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    723,830

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    CLIENTS OF THE FILING INVESTMENT MANAGER HAVE THE RIGHT TO RECEIVE AND THE ULTIMATE POWER TO DIRECT THE RECEIPT OF DIVIDENDS FROM, OR THE PROCEEDS OF SALE OF THE SECURITIES REPORTED ON HEREINABOVE. NO INTEREST OF ANY ONE OF SUCH CLIENTS RELATES TO MORE THAN FIVE PERCENT OF THE CLASS.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    PZENA INVESTMENT MANAGEMENT LLC
     
    Signature:s/Steven Coffey
    Name/Title:Chief Legal Risk Officer & Chief Compliance Officer
    Date:04/28/2025
    Get the next $PAHC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAHC

    DatePrice TargetRatingAnalyst
    7/7/2025$35.00Neutral → Overweight
    Analyst
    6/16/2025$24.00Underperform → Neutral
    BNP Paribas Exane
    9/10/2024$22.00Neutral
    JP Morgan
    12/7/2023$9.00Underperform
    Exane BNP Paribas
    12/21/2022$18.00Buy
    ROTH Capital
    7/25/2022$22.00Equal Weight → Underweight
    Barclays
    1/10/2022$23.00Underweight → Equal-Weight
    Barclays
    11/18/2021$23.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $PAHC
    SEC Filings

    View All

    SEC Form DEFA14A filed by Phibro Animal Health Corporation

    DEFA14A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)

    9/19/25 4:15:06 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Phibro Animal Health Corporation

    DEF 14A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)

    9/19/25 4:10:42 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)

    8/27/25 5:08:02 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Corcoran E Thomas bought $110,500 worth of shares (5,000 units at $22.10), increasing direct ownership by 20% to 30,000 units (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    2/26/25 4:15:17 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Corcoran E Thomas bought $100,100 worth of shares (5,000 units at $20.02), increasing direct ownership by 25% to 25,000 units (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    9/6/24 4:34:30 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Phibro Animal Health upgraded by Analyst with a new price target

    Analyst upgraded Phibro Animal Health from Neutral to Overweight and set a new price target of $35.00

    7/7/25 8:10:48 AM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Phibro Animal Health from Underperform to Neutral and set a new price target of $24.00

    6/16/25 8:16:19 AM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JP Morgan initiated coverage on Phibro Animal Health with a new price target

    JP Morgan initiated coverage of Phibro Animal Health with a rating of Neutral and set a new price target of $22.00

    9/10/24 7:55:45 AM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Phibro Animal Health Corporation Announces Licensing Agreement with Lighthouse Pharmaceuticals, Inc. for Innovative Periodontal Health Asset for Dogs

    Phibro Animal Health Corporation (NASDAQ:PAHC), a global leader in animal health and nutrition, today announced it has entered into a licensing agreement with Lighthouse Pharmaceuticals, Inc. for a novel therapeutic asset targeting periodontal health in companion animals. This agreement grants Phibro exclusive rights to develop, manufacture, and commercialize Lighthouse Pharma's proprietary compound for canine periodontal care. The compound represents a promising advancement in veterinary dental health, addressing a widespread and often under-treated condition in dogs. "We are excited to partner with Lighthouse Pharma to help develop and commercialize a new solution for periodontal dise

    10/9/25 4:30:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation to Participate at Morgan Stanley Annual Global Healthcare Conference

    Phibro Animal Health Corporation (NASDAQ:PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference. Chief Financial Officer, Glenn David will address financial analysts and investors on Tuesday, September 9, 2025, at 12:20 PM ET at the Sheraton New York Times Square Hotel. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com. A replay of the session will be available and archived on the company's website. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. W

    9/2/25 4:00:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

    Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2025 and provided its financial guidance for the year ending June 30, 2026. Highlights for the three months ended June 30, 2025 (compared to the three months ended June 30, 2024) Net sales of $378.7 million, an increase of $105.5 million, or 39% Net income of $17.2 million, an increase of $16.5 million Diluted earnings per share of $0.42, an increase of $0.40 Adjusted EBITDA of $50.0 million, an increase of $16.5 million, or 49% Adjusted net income of $23.2 million, an increase of $6.6 million, or 39% Adjusted

    8/27/25 4:57:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Bendheim Jack sold $834,412 worth of shares (20,664 units at $40.38) (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    10/1/25 4:10:25 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Bendheim Jack sold $282,732 worth of shares (7,022 units at $40.26) and converted options into 30,000 shares (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    9/22/25 6:32:03 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Bendheim Jack sold $857,313 worth of shares (21,120 units at $40.59) (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    9/11/25 8:56:36 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Leadership Updates

    Live Leadership Updates

    View All

    Phibro Animal Health Corporation Announces the Appointment of Joyce J. Lee to Its Board of Directors

    The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Joyce J. Lee, MBA, as a Class II director of the Company, effective immediately. Ms. Lee will be an independent director. Her appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Ms. Lee brings a wealth of expertise and leadership to our Board of Directors, most recently serving as President of Cobb Vantress LLC, a premier genetics company dedicated to feeding the world through responsible genetic innovation. Before joining Cobb Vantress, Ms. Lee held executive positions at Elanco, Bayer Animal Health, and Zoetis.

    1/23/25 4:45:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TerraCycle Appoints New Chief Financial Officer to Global Leadership Team

    Damian Finio to Succeed Javier Daly as Chief Financial Officer TRENTON, N.J., Sept. 6, 2023 /PRNewswire/ --­ TerraCycle Inc., the international leader in innovative sustainability solutions, today announced Damian Finio will join the company's global leadership team as Chief Financial Officer, effective October 2. Finio most recently served as Chief Financial Officer of Phibro Animal Health Corporation (NASDAQ:PAHC) and joins TerraCycle with more than 30 years of financial management experience, primarily in the life sciences industry having spent nearly half of his career at

    9/6/23 12:20:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation Announces the Appointment of Alejandro Bernal to Its Board of Directors and Declares Quarterly Dividend

    The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Alejandro Bernal, DVM, MS, MBA, as a Class III director of the Company, effective immediately. Mr. Bernal will be an independent director. His appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Mr. Bernal recently became Chief Executive Officer of PetDx® – The Liquid Biopsy Company for Pets™, a company based in San Diego, CA, and focused on early detection of cancer using Next Generation Sequencing (NGS) technology. Prior to joining PetDx, Mr. Bernal was the President for Mars Veterinary Health International and

    2/6/23 4:15:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Financials

    Live finance-specific insights

    View All

    Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

    Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2025 and provided its financial guidance for the year ending June 30, 2026. Highlights for the three months ended June 30, 2025 (compared to the three months ended June 30, 2024) Net sales of $378.7 million, an increase of $105.5 million, or 39% Net income of $17.2 million, an increase of $16.5 million Diluted earnings per share of $0.42, an increase of $0.40 Adjusted EBITDA of $50.0 million, an increase of $16.5 million, or 49% Adjusted net income of $23.2 million, an increase of $6.6 million, or 39% Adjusted

    8/27/25 4:57:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2025 Results

    Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its fourth quarter and fiscal year 2025 financial results on Wednesday, August 27, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 28, 2025, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of

    8/20/25 4:00:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phibro Animal Health Corporation Declares Quarterly Dividend

    The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on September 24, 2025, to stockholders of record at the close of business on September 3, 2025. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please v

    7/29/25 4:10:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Phibro Animal Health Corporation

    SC 13D/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)

    11/15/24 4:15:40 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Phibro Animal Health Corporation

    SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)

    11/14/24 12:51:31 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Phibro Animal Health Corporation

    SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)

    11/12/24 4:55:22 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care